In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium‐Dependent β‐Catenin Activation
Advanced Science · 2026
DOI: 10.1002/advs.202521746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jie Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms, beta Catenin, Receptors, AMPA. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Foundation of Zhongshan Hospital.
Abstract (Originalsprache)
Peritoneal metastasis is the most lethal manifestation of gastric cancer, with a median survival of less than one year, highlighting the need for new therapeutic targets. Through an in vivo genome‐wide CRISPR/Cas9 screen, we identified GRIA2, an AMPA‐type glutamate receptor subunit, as a key driver of peritoneal metastasis. GRIA2 promotes gastric cancer cell migration, invasion, stemness, and adhesion to mesothelial cells in a glutamate‐dependent manner. Mechanistically, glutamate activates GRIA2, enhancing its interaction with GSK‐3β and inducing calcium influx, inhibiting GSK‐3β kinase activity and stabilizing β‐catenin, thereby activating the Wnt/β‐catenin signaling pathway. Single‐cell RNA sequencing revealed that cancer‐associated fibroblasts are the primary source of glutamate in the peritoneal microenvironment, which establishes a paracrine axis that enhances GRIA2‐driven metastasis. Pharmacological inhibition of AMPA receptors with NBQX and Selurampanel suppressed peritoneal metastasis in both cell line‐derived and patient‐derived organoid xenograft (PDOX) mouse models. In clinical analysis, GRIA2 expression in peritoneal metastases correlated with the levels of β‐catenin and phosphorylated GSK‐3β (serine 9), with high GRIA2 expression predicting poor prognosis. These findings suggest that GRIA2 is a novel therapeutic target, and AMPA receptor antagonists are promising agents for treating gastric cancer peritoneal metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
- Gastric Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China.
- Department of Pathology, Nippon Veterinary and Life Science University, Tokyo, Japan.
- Department of Pathology, Graduate School of Medicine, Fujita Health University, Toyoake, Japan.
Förderung
- Scientific Research Foundation of Zhongshan Hospital
Zitieren
APA
Sun, J., Yang, X., Jiang, W., Ji, C., Wu, Y., Sun, H., Liu, X., Yamamoto, M., Tsukamoto, T., Nomura, S., Zhao, J., Ruan, Y., Li, H., & Wang, X. (2026). In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium‐Dependent β‐Catenin Activation. Advanced Science. https://doi.org/10.1002/advs.202521746
Vancouver
Sun J, Yang X, Jiang W, Ji C, Wu Y, Sun H, et al. In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium‐Dependent β‐Catenin Activation. Advanced Science. 2026. doi:10.1002/advs.202521746
BibTeX
@article{Sun2026,
author = {Sun, Jie and Yang, Xu and Jiang, Wenchao and Ji, Chengbo and Wu, Yingying and Sun, Haoyu and Liu, Xinyou and Yamamoto, Masami and Tsukamoto, Tetsuya and Nomura, Sachiyo and Zhao, Junjie and Ruan, Yuanyuan and Li, Haojie and Wang, Xuefei},
title = {In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium‐Dependent β‐Catenin Activation},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521746}
}
EUVIMED